First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and…